Clinical Trials Browser

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT02489318 2026-04-13

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 2 FDA

Genitourinary

Prostatic Neoplasms

NCT02531516 2026-04-13

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

1,503 enrolled

Genitourinary

Prostatic Neoplasms

NCT03767244 2026-04-13

PROTEUS

Phase 3 Active not recruiting

2,517 enrolled

Genitourinary

Prostatic Neoplasms

NCT04557059 2026-04-13

PRIMORDIUM

Phase 3 Active not recruiting

693 enrolled

Genitourinary

Prostatic Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

599 enrolled

Genitourinary

Prostatic Neoplasms

NCT04513717 2026-04-03

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

2,753 enrolled

Genitourinary

Prostatic Neoplasms

NCT04493853 2026-04-01

CAPItello-281

Phase 3 Active not recruiting

1,012 enrolled

Genitourinary

Prostatic Neoplasms

NCT05678322 2026-03-25

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

Phase 3 Active not recruiting

26 enrolled 7 charts

Genitourinary

Prostatic Neoplasms

NCT04484818 2026-03-23

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Phase 3 Active not recruiting

27 enrolled

Genitourinary

Prostatic Neoplasms

NCT04689828 2026-03-23

PSMAfore

Phase 3 Active not recruiting

469 enrolled 11 charts 3 FDA

Genitourinary

Prostatic Neoplasms

NCT07477626 2026-03-17

RADVAN

Phase 3 Active not recruiting

374 enrolled

Genitourinary

Prostatic Neoplasms

NCT04720157 2026-03-11

PSMAddition

Phase 3 Active not recruiting

1,145 enrolled

Genitourinary

Prostatic Neoplasms

NCT05154162 2026-03-03

PRIMARY2

Phase 3 Active not recruiting

660 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03574571 2026-02-27

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Phase 3 Active not recruiting

732 enrolled

Genitourinary

Prostatic Neoplasms

NCT04455750 2026-02-05

CASPAR

Phase 3 Active not recruiting

61 enrolled

Genitourinary

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

Phase 3 Active not recruiting

455 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

1,380 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT03987386 2025-11-12

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3 Active not recruiting

186 enrolled

Genitourinary

Prostatic Neoplasms

NCT01368588 2025-10-28

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3 Active not recruiting

2,592 enrolled

Genitourinary

Prostatic Neoplasms

NCT02194842 2025-09-19

PEACE III

Phase 3 Active not recruiting

446 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01230866 2025-09-04

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

Phase 3 Active not recruiting

150 enrolled

Genitourinary

Prostatic Neoplasms

NCT05336786 2025-09-04

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Phase 3 Active not recruiting

70 enrolled

Genitourinary

Prostatic Neoplasms

NCT01407263 2025-08-14

Trial of Modifications to Radical Prostatectomy

Phase 3 Active not recruiting

3,204 enrolled

Genitourinary

Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

439 enrolled

Genitourinary

Prostatic Neoplasms

NCT01436968 2025-07-30

PrTK03

Phase 3 Active not recruiting

711 enrolled

Genitourinary

Prostatic Neoplasms

NCT04181203 2025-07-30

CARLHA-2

Phase 3 Active not recruiting

490 enrolled

Genitourinary

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Phase 3 Active not recruiting

1,068 enrolled 20 charts 2 FDA

Genitourinary

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Phase 3 Active not recruiting

925 enrolled 12 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT03531099 2025-06-22

HIFUSA

Phase 3 Active not recruiting

108 enrolled

Genitourinary

Prostatic Neoplasms

NCT02804815 2025-06-10

Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

Phase 3 Active not recruiting

11,000 enrolled

BreastGastrointestinalGenitourinary

Breast Neoplasms, Neoplasms, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms

NCT02446444 2025-05-30

ENZARAD

Phase 3 Active not recruiting

802 enrolled

Genitourinary

Prostatic Neoplasms

NCT03582774 2025-05-13

PSMA SRT

Phase 3 Active not recruiting

193 enrolled

Genitourinary

Prostatic Neoplasms

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Phase 3 Active not recruiting

1,792 enrolled 27 charts

Genitourinary

Prostatic Neoplasms

NCT04302454 2025-04-04

ADOPT

Phase 3 Active not recruiting

280 enrolled

Genitourinary

Prostatic Neoplasms

NCT02692105 2025-03-13

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

Phase 3 Active not recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT04557501 2025-03-13

PATRON

Phase 3 Active not recruiting

800 enrolled

Genitourinary

Prostatic Neoplasms

NCT05004285 2025-03-12

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

Phase 3 Active not recruiting

398 enrolled

Genitourinary

Prostatic Neoplasms

NCT05936658 2025-03-12

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

Phase 3 Active not recruiting

138 enrolled

Genitourinary

Prostatic Neoplasms

NCT05676203 2025-02-17

ARASAFE

Phase 3 Active not recruiting

250 enrolled

Genitourinary

Prostatic Neoplasms

NCT02446405 2025-02-06

ENZAMET

Phase 3 Active not recruiting

1,125 enrolled

Genitourinary

Prostatic Neoplasms

NCT00223145 2025-01-27

PCS III

Phase 3 Active not recruiting

600 enrolled

Genitourinary

Prostatic Neoplasms

NCT00223171 2025-01-27

PCS IV

Phase 3 Active not recruiting

630 enrolled

Genitourinary

Prostatic Neoplasms

NCT05348577 2025-01-27

CAPItello280

Phase 3 Active not recruiting

1,035 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02303327 2024-12-09

Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

Phase 3 Active not recruiting

307 enrolled

Genitourinary

Prostatic Neoplasms

NCT01444820 2024-12-04

Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

Phase 3 Active not recruiting

329 enrolled

Genitourinary

Prostatic Neoplasms

NCT01957436 2024-11-12

PEACE1

Phase 3 Active not recruiting

1,173 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

Clinical Trials

SPARTAN

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

TITAN

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

PROTEUS

PRIMORDIUM

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

CAPItello-281

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

PSMAfore

RADVAN

PSMAddition

PRIMARY2

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

CASPAR

SPLASH

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

CONTACT-02

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

PEACE III

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Trial of Modifications to Radical Prostatectomy

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

PrTK03

CARLHA-2

KEYNOTE-641

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

CYCLONE 3

HIFUSA

Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

ENZARAD

PSMA SRT

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

ADOPT

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

PATRON

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

ARASAFE

ENZAMET

PCS III

PCS IV

CAPItello280

Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

PEACE1